image
Healthcare - Biotechnology - NASDAQ - US
$ 4.265
-10.6 %
$ 111 M
Market Cap
-0.84
P/E
1. INTRINSIC VALUE

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever.[ Read More ]

The intrinsic value of one INO stock under the base case scenario is HIDDEN Compared to the current market price of 4.26 USD, Inovio Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INO

image
FINANCIALS
832 K REVENUE
-91.89%
-135 M OPERATING INCOME
49.46%
-135 M NET INCOME
51.71%
-124 M OPERATING CASH FLOW
42.48%
87.4 M INVESTING CASH FLOW
-20.29%
5 M FINANCING CASH FLOW
-93.90%
0 REVENUE
0.00%
-27.3 B OPERATING INCOME
-82279.58%
-87.8 B NET INCOME
-272287.24%
-84.4 B OPERATING CASH FLOW
-298934.45%
69.4 B INVESTING CASH FLOW
695958.40%
22.3 B FINANCING CASH FLOW
67432.65%
Balance Sheet Decomposition Inovio Pharmaceuticals, Inc.
image
Current Assets 153 M
Cash & Short-Term Investments 145 M
Receivables 2.41 M
Other Current Assets 5.41 M
Non-Current Assets 19.8 M
Long-Term Investments 2.78 M
PP&E 14.5 M
Other Non-Current Assets 2.6 M
Current Liabilities 42.6 M
Accounts Payable 4.65 M
Short-Term Debt 19.2 M
Other Current Liabilities 18.7 M
Non-Current Liabilities 13 M
Long-Term Debt 11 M
Other Non-Current Liabilities 1.99 M
EFFICIENCY
Earnings Waterfall Inovio Pharmaceuticals, Inc.
image
Revenue 832 K
Cost Of Revenue 3.5 M
Gross Profit -2.67 M
Operating Expenses 133 M
Operating Income -135 M
Other Expenses -109 K
Net Income -135 M
RATIOS
-321.09% GROSS MARGIN
-321.09%
-16253.01% OPERATING MARGIN
-16253.01%
-16239.87% NET MARGIN
-16239.87%
-115.14% ROE
-115.14%
-78.13% ROA
-78.13%
-100.83% ROIC
-100.83%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inovio Pharmaceuticals, Inc.
image
Net Income -135 M
Depreciation & Amortization 3.5 M
Capital Expenditures -321 K
Stock-Based Compensation 11.1 M
Change in Working Capital -10.3 M
Others 32.9 M
Free Cash Flow -125 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inovio Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for INO of $18 , with forecasts ranging from a low of $4 to a high of $40 .
INO Lowest Price Target Wall Street Target
4 USD -6.21%
INO Average Price Target Wall Street Target
18 USD 322.04%
INO Highest Price Target Wall Street Target
40 USD 837.87%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.069 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Inovio Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 05, 2023
Sell 3.19 K USD
Zoth Lota S.
Director
- 5700
0.56 USD
1 year ago
Mar 13, 2023
Sell 6.71 K USD
Weiner David B.
Director
- 5833
1.15 USD
1 year ago
Feb 27, 2023
Sell 14.9 K USD
Weiner David B.
Director
- 11668
1.28 USD
2 years ago
Aug 11, 2022
Sell 31.6 K USD
Weiner David B.
director:
- 11875
2.66 USD
2 years ago
Jul 20, 2022
Sell 4.5 K USD
BENITO SIMON X
director:
- 2000
2.25 USD
2 years ago
May 13, 2022
Sell 17.6 K USD
Weiner David B.
director:
- 9000
1.95 USD
2 years ago
May 13, 2022
Sell 7.13 K USD
Zoth Lota S.
director:
- 3600
1.98 USD
2 years ago
Mar 16, 2022
Sell 6.32 K USD
BENITO SIMON X
director:
- 2000
3.16 USD
2 years ago
Mar 11, 2022
Sell 13.1 K USD
Weiner David B.
director:
- 4083
3.2 USD
2 years ago
Mar 08, 2022
Sell 13.6 K USD
Weiner David B.
director:
- 4083
3.33 USD
2 years ago
Jan 19, 2022
Sell 8.54 K USD
BENITO SIMON X
Director
- 2000
4.27 USD
2 years ago
Jan 05, 2022
Sell 4.81 K USD
Zoth Lota S.
Director
- 961
5.01 USD
3 years ago
Aug 09, 2021
Sell 94.4 K USD
Humeau Laurent
Chief Scientific Officer
- 10317
9.15 USD
3 years ago
Jun 09, 2021
Sell 386 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 38535
10.01 USD
3 years ago
Jun 09, 2021
Sell 93.6 K USD
Humeau Laurent
Chief Scientific Officer
- 10318
9.07 USD
3 years ago
Jun 09, 2021
Sell 338 K USD
KIES PETER
CFO
- 33750
10.01 USD
3 years ago
Jun 03, 2021
Sell 80.3 K USD
KIES PETER
CFO
- 10000
8.03 USD
3 years ago
May 17, 2021
Sell 13.5 K USD
Zoth Lota S.
Director
- 2045
6.62 USD
3 years ago
May 17, 2021
Sell 20.2 K USD
Weiner David B.
Director
- 3045
6.62 USD
3 years ago
May 17, 2021
Sell 20.2 K USD
BENITO SIMON X
Director
- 3045
6.62 USD
3 years ago
Apr 21, 2021
Sell 85.2 K USD
KIES PETER
CFO
- 10000
8.52 USD
3 years ago
Apr 21, 2021
Sell 193 K USD
Weiner David B.
Director
- 22500
8.57 USD
3 years ago
Apr 21, 2021
Sell 34.9 K USD
Weiner David B.
Director
- 4083
8.54 USD
3 years ago
Apr 16, 2021
Sell 17.5 K USD
BENITO SIMON X
Director
- 2000
8.75 USD
3 years ago
Mar 26, 2021
Sell 42.2 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 4710
8.97 USD
3 years ago
Mar 16, 2021
Sell 20.8 K USD
BENITO SIMON X
Director
- 2000
10.41 USD
3 years ago
Mar 12, 2021
Sell 170 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 16881
10.06 USD
3 years ago
Mar 09, 2021
Sell 33.6 K USD
Weiner David B.
Director
- 3500
9.6003 USD
3 years ago
Mar 08, 2021
Sell 32.1 K USD
Weiner David B.
Director
- 3500
9.1814 USD
3 years ago
Feb 16, 2021
Sell 29.4 K USD
BENITO SIMON X
Director
- 2000
14.68 USD
3 years ago
Feb 01, 2021
Sell 1.5 M USD
Kim Jong Joseph
Chief Executive Officer
- 100000
15 USD
3 years ago
Feb 03, 2021
Sell 890 K USD
Kim Jong Joseph
Chief Executive Officer
- 62500
14.24 USD
3 years ago
Feb 01, 2021
Sell 337 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 22376
15.06 USD
3 years ago
Feb 01, 2021
Sell 89.4 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 5960
15 USD
3 years ago
Jan 28, 2021
Sell 201 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 16713
12.04 USD
3 years ago
Jan 27, 2021
Sell 269 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 22376
12.01 USD
3 years ago
Jan 27, 2021
Sell 71.8 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 5960
12.04 USD
3 years ago
Jan 15, 2021
Sell 301 K USD
KIES PETER
CFO
- 30000
10.0186 USD
3 years ago
Jan 05, 2021
Sell 9.11 K USD
Zoth Lota S.
Director
- 961
9.48 USD
3 years ago
Jan 04, 2021
Sell 24.8 K USD
BENITO SIMON X
Director
- 2750
9 USD
3 years ago
Dec 15, 2020
Sell 214 K USD
KIES PETER
CFO
- 20000
10.6853 USD
3 years ago
Dec 15, 2020
Sell 187 K USD
Weiner David B.
Director
- 17500
10.7058 USD
4 years ago
Nov 10, 2020
Sell 190 K USD
Humeau Laurent
Chief Scientific Officer
- 19466
9.75 USD
4 years ago
Aug 10, 2020
Sell 371 K USD
Humeau Laurent
Chief Scientific Officer
- 19467
19.0581 USD
4 years ago
Jul 30, 2020
Sell 2.11 M USD
Kim Jong Joseph
Chief Executive Officer
- 100000
21.1345 USD
4 years ago
Jul 15, 2020
Sell 873 K USD
KIES PETER
CFO
- 35000
24.9488 USD
4 years ago
Jun 30, 2020
Sell 928 K USD
KIES PETER
CFO
- 35000
26.5 USD
4 years ago
Jun 22, 2020
Sell 286 K USD
Humeau Laurent
Chief Scientific Officer
- 19467
14.7 USD
4 years ago
May 20, 2020
Sell 140 K USD
BENITO SIMON X
Director
- 8750
15.9536 USD
4 years ago
May 11, 2020
Sell 28.5 K USD
Weiner David B.
Director
- 2404
11.84 USD
4 years ago
Mar 10, 2020
Sell 32.6 K USD
Weiner David B.
Director
- 3500
9.32 USD
4 years ago
Mar 12, 2020
Sell 39 K USD
Weiner David B.
Director
- 3500
11.14 USD
4 years ago
Mar 09, 2020
Sell 63 K USD
Weiner David B.
Director
- 3500
18 USD
4 years ago
Jan 13, 2020
Bought 70 K USD
Kim Jong Joseph
Chief Executive Officer
+ 22500
3.11 USD
5 years ago
Aug 30, 2019
Bought 9.99 K USD
Humeau Laurent
Chief Scientific Officer
+ 4500
2.22 USD
5 years ago
Aug 01, 2019
Sell 44.5 K USD
Weiner David B.
Director
- 16352
2.72 USD
5 years ago
Jun 05, 2019
Bought 50 K USD
Humeau Laurent
Chief Scientific Officer
+ 20000
2.5 USD
5 years ago
May 31, 2019
Sell 1.22 M USD
Kim Jong Joseph
Chief Executive Officer
- 500000
2.4353 USD
5 years ago
May 31, 2019
Sell 1.2 M USD
Kim Jong Joseph
Chief Executive Officer
- 500000
2.4016 USD
5 years ago
Jun 03, 2019
Sell 1.91 M USD
Kim Jong Joseph
Chief Executive Officer
- 832848
2.2987 USD
5 years ago
Jun 03, 2019
Sell 685 K USD
Kim Jong Joseph
Chief Executive Officer
- 296705
2.3078 USD
5 years ago
May 21, 2019
Sell 331 K USD
Kim Jong Joseph
Chief Executive Officer
- 100000
3.31 USD
5 years ago
May 15, 2019
Sell 264 K USD
Kim Jong Joseph
Chief Executive Officer
- 75556
3.5 USD
5 years ago
May 16, 2019
Sell 214 K USD
Kim Jong Joseph
Chief Executive Officer
- 61212
3.5 USD
5 years ago
Nov 29, 2018
Sell 52.8 K USD
KIES PETER
CFO
- 10001
5.28 USD
6 years ago
Sep 12, 2018
Sell 263 K USD
Kim Jong Joseph
Chief Executive Officer
- 49060
5.37 USD
6 years ago
Jul 09, 2018
Sell 111 K USD
KIES PETER
CFO
- 25000
4.43 USD
6 years ago
Jul 10, 2018
Sell 44.5 K USD
KIES PETER
CFO
- 10000
4.45 USD
7. News
European And US Vaccine Stocks Are Under Pressure - Here's WHy Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. benzinga.com - 1 day ago
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode. seekingalpha.com - 2 days ago
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences  Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa. , Nov. 14, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments. prnewswire.com - 2 days ago
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UK PLYMOUTH MEETING, Pa. , Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients. prnewswire.com - 3 days ago
INOVIO to Present at Upcoming Scientific Conferences PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways Vaccines Summit (Boston, MA; November 13-15) Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis Abstracts from these conferences will be made available on INOVIO's website following each presentation. prnewswire.com - 1 week ago
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024 PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024. prnewswire.com - 1 week ago
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program. prnewswire.com - 3 weeks ago
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 1 month ago
INOVIO Reports Inducement Grants Under Inducement Plan PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan"). prnewswire.com - 1 month ago
INOVIO to Present at Upcoming Scientific Conferences PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways Date and Time: October 19, 2024, 6:00 - 8:15pm ET Location: Boston, MA ISV Congress 2024 Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 22, 2024, 4:20pm KSTLocation: Seoul, Korea Fall Voice Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 25 – October 26, 2024 Location: Phoenix, AZ World Vaccine Congress Europe Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIOTrack: Pre-Congress Workshop on Platform TechnologiesDate and Time: October 28, 2024, 10:00am CET Location: Barcelona, Spain Abstracts from these conferences will be made available on INOVIO's website following each presentation. prnewswire.com - 1 month ago
INOVIO to Present at Upcoming Scientific Conference PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology Date and Time: September 18, 2024, 3:20pm – 3:35pm CET Location: Rome, Italy The abstract from the conference will be made available on INOVIO's website following the data presentation. prnewswire.com - 1 month ago
Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operator Good afternoon ladies and gentlemen and welcome to the Inovio Second Quarter 2024 Financial Results Conference Call. seekingalpha.com - 3 months ago
8. Profile Summary

Inovio Pharmaceuticals, Inc. INO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 111 M
Dividend Yield 0.00%
Description Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Contact 660 West Germantown Pike, Plymouth Meeting, PA, 19462 https://www.inovio.com
IPO Date Dec. 8, 1998
Employees 127
Officers Thomas Hong Manager of Investor Relations Dr. Jeffrey Skolnik Senior Vice President of Clinical Development Mr. Shawn D. Bridy M.A., M.B.A. Senior Vice President of Business Development Mr. Robert L. Crotty J.D. General Counsel & Chief Compliance Officer Mr. Robert J. Juba Jr. Senior Vice President of Biological Manufacturing & Clinical Supply Management Dr. Jacqueline E. Shea Ph.D. Chief Executive Officer, President & Director Mr. Peter D. Kies Chief Financial Officer Dr. David Liebowitz M.D., Ph.D. Senior Vice President of Early-Stage Clinical Development Dr. Laurent M. Humeau Ph.D. Chief Scientific Officer & Chairman of the Scientific Advisory Board Mr. E. J. Brandreth MBA Senior Vice President of Quality Assurance